HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Cymbalta Halted By GMP Issues; “Approvable” Letter Issued Sept. 13

Executive Summary

Lilly plans to keep the fill-finish production of Cymbalta (duloxetine) in Indianapolis and resolve FDA's good manufacturing practices concerns rather than pursue an alternate manufacturing arrangement for the antidepressant, Lilly said after receiving an "approvable" letter Sept. 13
Advertisement

Related Content

UnitedHealth Rx Registry Will Test Four Highest Prescribed NMEs In 2004
UnitedHealth Rx Registry Will Test Four Highest Prescribed NMEs In 2004
Lilly Cymbalta Launched At Premium Price; Once-Daily Dose Encouraged
Lilly Cymbalta Launched At Premium Price; Once-Daily Dose Encouraged
Lilly Cymbalta Approval Timeline In Doubt After Delay In Second NDA
FDA Approval Is “First Action” For 32% Of NMEs; Rate Less Than Other NDAs
Lilly/Boehringer Duloxetine Co-Promotion Lets Lilly Focus On Cialis Launch
Lilly Dual-Acting Cymbalta Promoted By Dual Sales Force With Quintiles Deal
Lilly Cialis Using Alternate Manufacturing Facilities For 2nd Half 2003 Launch
Lilly Cialis Using Alternate Manufacturing Facilities For 2nd Half 2003 Launch
Advertisement
UsernamePublicRestriction

Register

PS040509

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel